Showing all 5 results
Atazanavir & Ritonavir Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Film-Coated Tablet, engineered for synchronized 24-hour viral suppression.
Active Ingredient Strength Primary Clinical Function Atazanavir (as Sulfate) USP/BP 300 mg The Antiviral Anchor: Blocks the maturation of HIV, preventing the spread of infection to CD4 cells. Ritonavir USP/BP 100 mg The Pharmacokinetic Booster: Inhibits liver metabolism to maintain high Atazanavir levels for 24 hours. Excipients Proprietary Matrix Bio-Enhancement System: Engineered to ensure maximum intestinal absorption, which is critical for PI-class medications. Indinavir sulphate Capsules
FreeIndinavir sulphate capsules contain the active antiviral drug and several inactive ingredients used to stabilize the medication for the treatment of HIV-1 infection.
Lamivudine, Zidovudine & Nevirapine Tablets
FreeProduct Composition & Strength
We supply this product as Film Coated Tablets (often White or Off-White). This FDC is designed for patients who have successfully completed the Nevirapine “lead-in” phase.
Active Ingredient Strength (Standard) Class Lamivudine USP/BP 150 mg NRTI (Cytidine Analog) Zidovudine USP/BP 300 mg NRTI (Thymidine Analog) Nevirapine USP/BP 200 mg NNRTI Excipients Q.S. Microcrystalline Cellulose / Sodium Starch Glycolate Lopinavir & Ritonavir Tablet
FreeProduct Composition & Strength
We supply this product as Film Coated Tablets (typically Yellow, Oval). The proprietary matrix ensures high bioavailability of poorly soluble Lopinavir.
Active Ingredient Strength (Standard) Therapeutic Role Lopinavir USP/BP 200 mg HIV-1 Protease Inhibitor Ritonavir USP/BP 50 mg Pharmacokinetic Booster (Pediatric Variant) 100 mg Lopinavir + 25 mg Ritonavir Pediatric HIV Management Excipients Q.S. Copovidone / Sorbitan Monolaurate / Silica Solubility Enhancers Tenofovir, Lamivudine & Dolutegravir Tablets
FreeProduct Composition & Strength
We supply this product as a highly advanced Film-Coated Tablet, packed strictly in heavy-gauge HDPE bottles with integrated silica gel desiccants. This packaging is absolutely non-negotiable, as Tenofovir is highly susceptible to hydrolytic degradation in humid environments.
Active Ingredient Strength Primary Clinical Function Tenofovir Disoproxil Fumarate (TDF) INN/Ph.Eur. 300 mg Potent Nucleotide Reverse Transcriptase Inhibitor (NRTI). Lamivudine (3TC) INN/Ph.Eur. 300 mg Synergistic Nucleoside Reverse Transcriptase Inhibitor (NRTI). Dolutegravir (DTG) INN/Ph.Eur. 50 mg Advanced Integrase Strand Transfer Inhibitor (INSTI). Excipients Microcrystalline Cellulose / Croscarmellose Sodium / Sodium Staryl Fumarate Diluent / Superdisintegrant / Lubricant (Engineered for uniform FDC dissolution)
